Victoria Jenkins is an accomplished leader in the biotechnology sector, spanning regulatory affairs, clinical development, clinical operations, biometrics and programme management. Currently serving as Vice President, Head of Regulatory Affairs, Clinical Operations & Biometrics at Bavarian Nordic, she is responsible for the operational and regulatory oversight of multiple clinical studies across all phases, including post-marketing research, as well as the regulatory life cycle management of Bavarian Nordic’s commercialised vaccines.
Victoria has played pivotal roles in the successful licensure and launch of vaccines in the US and Europe, including the recent review and approval of the Chikungunya vaccine VIMKUNYA by the FDA, EMA, and MHRA.
Prior to her current role, she held positions at Bavarian Nordic and GSK, where she led global medical affairs activities for vaccines such as Tdap, Shingles and influenza. Her early career included a PhD and postdoctoral research in tuberculosis drug discovery.
Victoria holds a PhD in Molecular Microbiology from Imperial College London, a BA in Natural Science from the University of Cambridge, and an MBA from IE Business School.